Optimized lactoferricin-derived peptides with +9 charge and moderate hydrophobicity selectively killed melanoma cells, including in realistic 3D tumor models.
+9 net chargewas the optimal design parameter for selective melanoma killing while sparing normal cells
What the researchers found
The researchers tested a set of modified di-peptides (doubled versions) derived from LF11, an 11-amino-acid fragment of human lactoferricin. They systematically varied length, positive charge, and hydrophobicity to find the optimal cancer-killing design.
The winners were R-DIM-P-LF11-215 and DIM-LF11-322, both with a net charge of +9 and moderate hydrophobicity. These showed the highest specific antitumor activity in standard 2D cultures and maintained their cancer-killing specificity in 3D multicellular tumor spheroids (MCTS).
One peptide, DIM-LF11-339, was highly hydrophobic and killed cancer cells in 2D but performed poorly in 3D. It could only kill cells at the outer edge of tumor spheroids, suggesting that too much hydrophobicity prevents peptides from penetrating into the center of solid tumors.
The peptides kill cancer cells by targeting phosphatidylserine, a lipid that sits on the outside of cancer cell membranes but stays hidden inside normal cell membranes. This is what gives the peptides their cancer specificity.
Why it matters
Most cancer drugs also damage healthy cells. These peptides selectively target a physical difference between cancer and normal cell membranes: the location of phosphatidylserine. The 3D spheroid data is especially valuable because flat cell cultures often overpredict drug effectiveness. The finding that moderate hydrophobicity outperforms high hydrophobicity provides a clear design rule for future peptide drugs.
The numbers in context
+9 net charge optimal; moderate hydrophobicity best; 3D spheroid penetration failed for highly hydrophobic variant
How the study worked
Tested in lab dishes using melanoma cells (in vitro). Standard 2D cell cultures were used first, then 3D multicellular tumor spheroids to better mimic real tumor tissue. Cell viability, apoptosis (programmed cell death), and membrane targeting were measured. Non-cancerous cells served as specificity controls.
Who was studied
Melanoma cell lines in 2D and 3D culture models
What this study cannot tell us
Tested only on melanoma cells in lab dishes, not in animals or humans. The 3D spheroids are more realistic than flat cultures but still lack blood vessels, immune cells, and the full complexity of real tumors. Only one cancer type (melanoma) was tested. No pharmacokinetic data on how these peptides would behave in a living body.
How to read the evidence
Preliminary evidence. Cell culture results including 3D spheroids are promising but lack animal model validation.
When this study was published
Published in 2020. Anti-cancer peptide research has continued to advance toward clinical candidates.
The bigger picture
Most cancer drugs damage healthy cells alongside tumors. These peptides exploit a physical difference between cancer and normal cell membranes — the location of phosphatidylserine — to achieve selectivity. This approach could lead to cancer treatments with fewer side effects.
Questions still open
- Will these peptides work against other cancer types beyond melanoma?
- Can the selectivity hold up in animal models with intact immune systems?
- What is the optimal delivery method for systemic use?
Common questions
How do these peptides tell cancer cells from normal cells?
Why test in 3D spheroids instead of just flat cell cultures?
Read the original research
Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.
Biochimica et biophysica acta. Biomembranes, 1862(8), 183264
Citation
Grissenberger, Sarah; Riedl, Sabrina; Rinner, Beate; Leber, Regina; Zweytick, Dagmar. (2020). Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.. Biochimica et biophysica acta. Biomembranes, 1862(8), 183264. https://doi.org/10.1016/j.bbamem.2020.183264